XBiotech Inc. (NASDAQ:XBIT - Get Free Report)'s share price passed below its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $3.10 and traded as low as $2.84. XBiotech shares last traded at $2.88, with a volume of 38,981 shares trading hands.
XBiotech Stock Up 2.0%
The stock has a 50 day moving average price of $3.09 and a 200 day moving average price of $4.28. The stock has a market capitalization of $92.68 million, a price-to-earnings ratio of -2.81 and a beta of 0.98.
XBiotech (NASDAQ:XBIT - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) EPS for the quarter.
Institutional Investors Weigh In On XBiotech
Hedge funds have recently added to or reduced their stakes in the business. Barclays PLC increased its holdings in shares of XBiotech by 13.9% during the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after acquiring an additional 3,661 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of XBiotech by 42.0% during the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock valued at $79,000 after acquiring an additional 5,887 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of XBiotech by 68.2% during the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after acquiring an additional 5,930 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of XBiotech by 7.5% during the fourth quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company's stock valued at $360,000 after acquiring an additional 6,328 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of XBiotech by 15.3% during the first quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company's stock valued at $218,000 after acquiring an additional 8,918 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Recommended Stories
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
